SXTC NASDAQ
China SXT Pharmaceuticals, Inc.
1W: -6.2%
1M: +8.6%
3M: +0.8%
YTD: -99.1%
1Y: +47.0%
3Y: -90.2%
5Y: -99.9%
$2.41
-0.55 (-18.58%)
Weekly Expected Move ±23.2%
$1
$2
$2
$3
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$1M
-38.4% ▼
5Y CAGR: -25.8%
Gross Profit
$183K
-50.1% ▼
5Y CAGR: -42.2%
Operating Income
-$7M
-165.7% ▼
Net Income
-$6M
-87.8% ▼
EPS (Diluted)
$-9.13
-11.6% ▼
EBITDA
-$7M
-171.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $3M | $2M | $2M | $2M | $1M |
| YoY Growth | -45.5% | -24.2% | -2.2% | -9.7% | -38.4% |
| Cost of Revenue | $1M | $2M | $1M | $1M | $889K |
| Gross Profit | $1M | $426K | $554K | $367K | $183K |
| Gross Margin | 48.1% | 21.6% | 28.7% | 21.1% | 17.1% |
| R&D Expenses | $0 | $0 | $184K | $191K | $179K |
| SG&A Expenses | $6M | $6M | $3M | $3M | $7M |
| Operating Expenses | $6M | $6M | $3M | $3M | $7M |
| Operating Income | -$5M | -$6M | -$3M | -$3M | -$7M |
| Operating Margin | -199.4% | -284.4% | -130.4% | -154.0% | -664.1% |
| Interest Expense | $37K | $477K | $544K | $648K | $63K |
| Income Before Tax | -$5M | -$6M | -$3M | -$3M | -$6M |
| Tax Expense | $328K | $0 | $0 | $0 | $131K |
| Net Income | -$6M | -$6M | -$3M | -$3M | -$6M |
| Net Margin | -220.4% | -301.0% | -160.7% | -189.8% | -578.5% |
| EPS (Diluted) | $-137.92 | $-22.23 | $-3.57 | $-8.18 | $-9.13 |
| EBITDA | -$5M | -$5M | -$2M | -$3M | -$7M |
| Shares Outstanding | 41591 | 266973 | 867422 | 403920 | 679648 |